Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

5(71.4%)

Phase 2

1(14.3%)

Phase 4

1(14.3%)

7Total

Phase 1(5)

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06157151Phase 2Recruiting

PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Role: lead

NCT05694364Phase 1Completed

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Role: collaborator

NCT06538480Phase 4Recruiting

Zopa Retreatment and Vector Shedding in Adults With RRP

Role: lead

NCT04724980Phase 1Active Not Recruiting

Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis

Role: lead

NCT03927261Phase 1Active Not Recruiting

PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

Role: lead

NCT03907527Phase 1Active Not Recruiting

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Role: lead

NCT03409627Phase 1Completed

Novel INXN-4001 Triple Effector Plasmid in Heart Failure

Role: collaborator

All 7 trials loaded